Blindness–Scoliosis–Arachnodactyly syndrome is a very rare genetic condition that mainly affects the eyes and the skeleton. People develop progressive vision loss that can lead to blindness, together with curvature of the spine (scoliosis or kyphoscoliosis) and long, slender fingers and toes (arachnodactyly). Symptoms usually start in childhood or the teen years and can worsen over time. Genetic Rare Disease Center

Doctors recognized this syndrome in families where several people had the same combination of eye problems and skeletal changes. In some families, vision first declines because the lens of the eye becomes displaced, followed by complications like retinal detachment; in parallel, scoliosis progresses and arachnodactyly is seen in the hands and feet. PMC

Because only a handful of families have been reported worldwide, exact genes and subtypes are still being studied. Some resources list autosomal-dominant inheritance, while detailed studies in a consanguineous (related-parents) family suggest a recessive pattern and point to a region on chromosome 14 for further research. In short: the inheritance pattern may vary by family, and genetic testing plus expert review are important. Genetic Rare Disease Center+1

Other names

• Blindness-scoliosis-arachnodactyly syndrome (BSAS). Genetic Rare Disease Center

• Scoliosis, arachnodactyly, and blindness (used by some databases). MalaCards

---

Types

There are no official, universally accepted subtypes yet. But for day-to-day care, doctors may think in these clinical patterns:

1. Eye-predominant pattern
   Vision changes (lens displacement, retinal problems) appear early and dominate care needs; scoliosis and arachnodactyly are present but milder. Genetic Rare Disease Center+1

2. Skeletal-predominant pattern
   Progressive scoliosis/kyphoscoliosis and obvious arachnodactyly drive care; vision loss occurs later or progresses more slowly. Genetic Rare Disease Center

3. Mixed pattern
   Eye and spine features progress together; this is common in published families. PMC

4. By suspected inheritance

   • Dominant-like families (one affected parent may pass it on). Genetic Rare Disease Center

   • Recessive-like families (often with parental relatedness; several affected siblings). PMC

These “types” help plan surveillance (for eyes vs. spine) but do not replace genetic diagnosis. Genetic Rare Disease Center

---

Causes

In rare syndromes, “causes” refers to underlying genetic and biological reasons and to mechanisms that lead to the main features. Where evidence is still emerging, I say so.

1. Genetic mutation(s) causing a rare, inherited disorder (the core cause). Genetic Rare Disease Center

2. Possible autosomal-dominant transmission in some families. Genetic Rare Disease Center

3. Possible autosomal-recessive transmission in consanguineous families. PMC

4. Defects in connective-tissue pathways suggested by the “marfanoid” feature mix (arachnodactyly, scoliosis). Evidence is indirect and based on clinical overlap. PMC

5. Chromosome 14 candidate region (14q) identified by autozygosity mapping in one family (gene not yet proven). PMC

6. Lens dislocation (ectopia lentis/lens subluxation) leading to progressive vision loss and later complications. PMC

7. Retinal detachment secondary to lens problems or vitreoretinal traction, causing severe visual loss. PMC

8. Abnormal retinal pigment epithelium contributing to visual dysfunction. Genetic Rare Disease Center

9. Microphakia (small lens) predisposing to lens instability and refractive shifts. Genetic Rare Disease Center

10. Cataract formation (lens clouding) worsening vision. Genetic Rare Disease Center

11. Microcornea/phthisis bulbi in advanced cases, reflecting severe ocular damage over time. PMC

12. Progressive scoliosis/kyphoscoliosis, likely from connective-tissue and growth-plate biology rather than muscle disease. Genetic Rare Disease Center

13. Arachnodactyly (long, slender digits) linked to abnormal connective-tissue structure. Genetic Rare Disease Center

14. Developmental anomalies during embryogenesis (category placement for BSAS among rare developmental disorders). MalaCards

15. Pathway candidates (research stage)—TGF-beta–related extracellular-matrix components (e.g., LTBP2 region explored but no mutation found in one study). Hypothesis, not confirmed. PMC

16. Pathway candidates (research stage)—Notch-related genes influencing spinal development (e.g., PSEN1/NUMB discussed as candidates). Hypothesis, not confirmed. PMC

17. Marfan/Beals differential ruled out in reported families, implying a distinct cause from classic FBN1/FBN2 disorders (testing negative in one study). PMC

18. Age of onset factors—features typically begin in childhood/adolescence, suggesting growth-related triggers of expression. Genetic Rare Disease Center

19. Family clustering—multiple affected siblings or parent-child transmission supports a hereditary cause rather than environmental exposure. Genetic Rare Disease Center+1

20. Extreme rarity—few families worldwide means the gene(s) may be very uncommon or private to certain lineages; discovery is ongoing. MalaCards+1

---

Common symptoms

1. Progressive vision loss – eyesight slowly worsens and can end in blindness without timely care. Genetic Rare Disease Center

2. Blindness – advanced outcome in reported families, especially after retinal detachment. Genetic Rare Disease Center+1

3. Lens subluxation (partial lens dislocation) – lens slips from normal position, causing blurred or double vision. Genetic Rare Disease Center

4. Retinal detachment – the retina peels off the eye wall; this is an emergency and can cause permanent vision loss. Genetic Rare Disease Center

5. Cataract – clouding of the lens, adding to visual decline. Genetic Rare Disease Center

6. Abnormal retinal pigmentation – changes in the retinal pigment layer that affect vision quality. Genetic Rare Disease Center

7. Strabismus/esotropia (eye misalignment) – eyes turn in or are misaligned, reducing depth perception. Genetic Rare Disease Center

8. Microphakia (small lens) – a small lens that is unstable and refracts light abnormally. Genetic Rare Disease Center

9. Scoliosis – sideways curvature of the spine, sometimes severe or progressive. Genetic Rare Disease Center

10. Kyphoscoliosis – combined forward bend and sideways curve; can affect breathing and posture. Genetic Rare Disease Center

11. Arachnodactyly – long, slender fingers/toes (“spider fingers”) easily seen on exam. Genetic Rare Disease Center

12. Microcornea (small cornea) and phthisis (shrunken eye) – reported in advanced cases after repeated eye damage. PMC

13. Visual refractive shifts – severe myopia turning to hyperopia after lens displacement, reflecting optical changes. PMC

14. Headaches/eye strain – secondary to focusing problems and misalignment (supportive symptom; varies). Genetic Rare Disease Center

15. Back pain or stiffness – from scoliosis progression and muscle imbalance. Genetic Rare Disease Center

(People may have only some of these. The mix and timing vary by family.) Genetic Rare Disease Center

---

Diagnostic tests

A) Physical exam (bedside assessment)

1. General physical and family history – look for similar features in relatives; ask when vision or spine issues began. Genetic Rare Disease Center

2. Spine inspection and forward-bend test – screens for scoliosis/kyphoscoliosis; measures curve progression. Genetic Rare Disease Center

3. Hand/foot exam for arachnodactyly – notes long, slender digits and any contractures. Genetic Rare Disease Center

4. Posture, gait, and height/arm-span checks – track growth and balance as scoliosis advances. Genetic Rare Disease Center

5. Basic neurologic/respiratory check – monitors for breathing impact or nerve symptoms from severe spinal curves. Genetic Rare Disease Center

B) Manual/office tests (targeted clinical maneuvers)

6. Cover–uncover and Hirschberg tests – quick checks for strabismus/esotropia in clinic. Genetic Rare Disease Center

7. Visual acuity testing (Snellen/LogMAR) – measures how well each eye sees at baseline and over time. Genetic Rare Disease Center

8. Refraction testing – identifies myopia/hyperopia and tracks shifts after lens subluxation. PMC

9. Slit-lamp exam – direct view of the cornea and lens to confirm cataract, microphakia, or lens displacement. Genetic Rare Disease Center

10. Ophthalmoscopy (dilated fundus exam) – looks for retinal tears, detachment, or pigment changes. Genetic Rare Disease Center

C) Lab and pathological / genetic testing

11. Comprehensive genetic counseling session – clarifies inheritance risks (dominant vs recessive features across families). Genetic Rare Disease Center+1

12. Genome-wide SNP microarray / autozygosity mapping – helpful in suspected recessive families with related parents; used in research to map candidate regions. PMC

13. Gene panel or exome sequencing – may identify causal variants; also rules out Marfan (FBN1) and Beals/CCA (FBN2) where clinically overlapping. PMC

14. Targeted testing of candidate genes when guided by research (e.g., exploring 14q region in specific pedigrees), understanding that findings are not yet definitive. PMC

15. Basic labs as needed before surgery (cataract repair or scoliosis surgery) – routine safety workup; not diagnostic of BSAS itself. (Clinical practice point.)

D) Electrodiagnostic tests

16. Electroretinography (ERG) – measures retinal function; helpful when media is cloudy or retina looks abnormal. Genetic Rare Disease Center

17. Visual evoked potentials (VEP) – assesses the visual pathway to the brain; useful in severe ocular disease to gauge remaining function. Genetic Rare Disease Center

E) Imaging tests

18. Spine X-rays (standing PA and lateral) – quantify curve magnitude (Cobb angle) and monitor change over time. Genetic Rare Disease Center

19. Spine MRI (when indicated) – evaluates spinal cord and structural anatomy, especially pre-op or with neurologic signs. Genetic Rare Disease Center

20. Ocular imaging

• OCT (optical coherence tomography) for macula/retina status;

• B-scan ultrasound when cataract or small opaque cornea blocks the view;

• Wide-field retinal imaging to map peripheral tears/detachments. Genetic Rare Disease Center

Non-pharmacological treatments

1. Vision rehabilitation program.
   Description: Structured training with a low-vision specialist helps you use remaining sight efficiently. It includes device trials (magnifiers, telescopes, high-contrast lighting), reading aids (large-print, e-readers with zoom/voice), mobility training (white cane techniques), and home/work adaptations (contrast strips on stairs, glare control, labelers). Counseling addresses independence and safety. Purpose: Improve daily function, independence, and quality of life despite low vision. Mechanism: Compensates for lost acuity/field by optimizing environment, magnification, contrast, and alternative sensory cues. National Eye Institute+2AAO Journal+2

2. Regular dilated retina surveillance.
   Description: Scheduled dilated exams (and OCT/widefield imaging as needed) to catch tears early. Purpose: Prevent retinal detachment or treat it promptly. Mechanism: Identify and seal breaks (laser/cryotherapy) before fluid lifts the retina. American Academy of Ophthalmology+1

3. Education on retinal warning symptoms.
   Description: Teach “flashes, sudden floaters, dark curtain” as emergency signs. Purpose: Speed urgent care. Mechanism: Early presentation enables simpler, vision-saving procedures. EyeWiki

4. Activity and trauma precautions.
   Description: Protective eyewear; avoid high-impact eye trauma. Purpose: Lower risk of lens/retina injury. Mechanism: Reduces mechanical stress on fragile zonules/retina. EyeWiki

5. Specialist management of lens subluxation.
   Description: Close follow-up; consider capsular support devices or surgery when indicated. Purpose: Maintain vision and prevent pressure spikes/inflammation. Mechanism: Stabilize or remove the unstable lens; restore optical focus. AAO Journal+1

6. Scoliosis-specific physical therapy (Schroth-type).
   Description: Supervised exercises for posture, asymmetric muscle strengthening, rib cage derotation, and breathing. Purpose: Limit curve progression and improve pain/function. Mechanism: Neuromuscular re-education and spinal unloading. BioMed Central+1

7. Bracing when criteria are met.
   Description: Custom brace (adolescent curves, and selective adult use for pain/support). Purpose: Slow curve progression during growth or provide symptomatic support. Mechanism: External forces counter deforming growth/mechanics. OrthoInfo+1

8. Ergonomics & core conditioning.
   Description: Posture coaching, workstation setup, core/back endurance training. Purpose: Reduce pain/fatigue; protect the spine. Mechanism: Improves load sharing and spinal stability. PMC

9. Pain self-management (non-drug).
   Description: Heat/ice, pacing, relaxation, CBT-based pain coping, sleep hygiene. Purpose: Reduce chronic back pain impact. Mechanism: Modulates pain pathways and muscle tension. (General pain-rehab evidence.)

10. Orientation & mobility (O&M) training.
    Description: Safe travel with reduced vision (route planning, cane skills, street crossing). Purpose: Safety/independence outside the home. Mechanism: Replaces visual navigation with tactile/auditory strategies. National Eye Institute

11. Assistive technology.
    Description: Screen readers, text-to-speech, contrast themes, video magnifier (CCTV). Purpose: Access reading/education/work. Mechanism: Digital magnification and audio output bypass reduced acuity. National Eye Institute

12. Lighting and glare control.
    Description: Task lighting, shades, filters, hats. Purpose: Better contrast and comfort. Mechanism: Improves signal-to-noise for remaining retinal function. National Eye Institute

13. Home safety modifications.
    Description: High-contrast edge marking, decluttering, tactile cues, talking appliances. Purpose: Prevent falls/injuries. Mechanism: Environmental compensation for vision loss. National Eye Institute

14. School/work accommodations.
    Description: Extra time, enlarged materials, seating, digital tools. Purpose: Equal access to learning/tasks. Mechanism: Reasonable adjustments per function. National Eye Institute

15. Psychological support.
    Description: Counseling/peer support for coping with disability. Purpose: Reduce anxiety/depression; improve adherence. Mechanism: Skills for adjustment and resilience. (Rehab literature.)

16. Nutritional optimization for bone health.
    Description: Adequate vitamin D and calcium from diet/supplements as needed. Purpose: Support skeletal health in scoliosis care. Mechanism: Vitamin D aids calcium absorption; calcium supports bone mineralization. Office of Dietary Supplements+1

17. Smoking cessation & alcohol moderation.
    Description: Eliminate smoking; limit alcohol. Purpose: Better healing/bone/eye health. Mechanism: Reduces oxidative and vascular stress. (Public-health consensus.)

18. Regular aerobic & strength exercise.
    Description: Safe, supervised plan to maintain fitness and back endurance. Purpose: Less pain, better function and mood. Mechanism: Anti-inflammatory, neuromuscular conditioning. (Orthopedic rehab evidence.)

19. Community low-vision resources.
    Description: Registry referrals and local services. Purpose: Practical help and devices. Mechanism: Connects patients to vetted providers and funding programs. National Eye Institute

20. Timely surgical referral (when indicated).
    Description: Escalate to retina or spine surgery if conservative measures fail or vision is threatened. Purpose: Preserve vision and prevent severe deformity. Mechanism: Structural repair (retina/lens) or deformity correction (spine). EyeWiki+1

---

Drug treatments

Important: These medicines treat complications (e.g., glaucoma risk from lens subluxation, retinal surgery care, spine pain). Doses/timing must be individualized by your clinicians.

1. Acetazolamide (Diamox®; tabs/IV). Class: carbonic anhydrase inhibitor. Typical dose/time: e.g., 250–500 mg PO/IV as directed for short-term IOP lowering. Purpose: Temporarily reduce eye pressure in lens-induced or peri-operative situations. Mechanism: Decreases aqueous humor production. Key side effects: paresthesias, fatigue, metabolic acidosis, kidney stones; avoid in sulfonamide allergy. FDA Access Data+1

2. Timolol ophthalmic (various; including Timoptic®, Timolol GFS). Class: topical β-blocker. Dose: 1 drop once or twice daily per product. Purpose: Lower IOP when glaucoma risk is present. Mechanism: ↓ aqueous production. Side effects: bradycardia/bronchospasm—avoid in asthma/COPD. FDA Access Data+1

3. Latanoprost ophthalmic (Xalatan®/Iyuzeh™). Class: prostaglandin analog. Dose: 1 drop nightly. Purpose: IOP control. Mechanism: ↑ uveoscleral outflow. Side effects: iris darkening, eyelash growth, irritation. FDA Access Data+1

4. Brimonidine ophthalmic (Alphagan®/Alphagan P®). Class: α2-agonist. Dose: typically TID (or per label). Purpose: Additional IOP lowering. Mechanism: ↓ aqueous production, ↑ uveoscleral outflow. Side effects: dry mouth, fatigue; caution in children. FDA Access Data+1

5. Dorzolamide–timolol combo (Cosopt®). Class: CAI + β-blocker. Dose: as labeled. Purpose: Step-up IOP control when monotherapy insufficient. Side effects: as above for components. FDA Access Data

6. Pilocarpine ophthalmic (select cases). Class: miotic. Purpose: Temporize pupil block in certain lens positions (specialist-directed). Mechanism: Pupillary constriction opens angle in some scenarios. Caution: Not for everyone—specialist decision. (General ophthalmology labels/guidance.)

7. Prednisolone acetate ophthalmic (Pred Forte®/Omnipred®). Class: steroid. Dose: per surgeon. Purpose: Control anterior-segment inflammation post-op or with lens issues. Mechanism: Anti-inflammatory. Side effects: can raise IOP—monitor. FDA Access Data+1

8. Ketorolac ophthalmic (Acular®/Acuvail®). Class: NSAID. Purpose: Post-op pain/inflammation (e.g., cataract-related). Mechanism: COX inhibition. Side effects: stinging; rare corneal effects. FDA Access Data+1

9. Moxifloxacin ophthalmic (Vigamox®/Moxeza®). Class: fluoroquinolone antibiotic. Purpose: Peri-operative prophylaxis or treatment of ocular surface infection per surgeon. Mechanism: Inhibits bacterial DNA gyrase/topo IV. Side effects: irritation. FDA Access Data+1

10. Ofloxacin ophthalmic (Ocuflox®). Class: fluoroquinolone. Purpose: Similar peri-operative/therapeutic use per surgeon. Mechanism: as above. Side effects: irritation, bitter taste. FDA Access Data+1

11. Acetaminophen (oral/IV). Class: analgesic/antipyretic. Dose: follow label max (account for all sources). Purpose: First-line pain control for back/eye-surgery discomfort. Mechanism: central COX modulation. Side effects: liver toxicity if overdose. FDA Access Data+1

12. Ibuprofen (OTC; Advil®/Motrin®). Class: NSAID. Dose: per label; lowest effective dose. Purpose: Musculoskeletal pain relief. Mechanism: COX inhibition. Risks: GI/cardiovascular—avoid if surgeon advises. FDA Access Data+1

13. Naproxen / Naproxen sodium (Rx/OTC). Class: NSAID. Purpose: Back pain relief; longer-acting option. Risks: boxed warnings for GI/CV events; not around certain surgeries unless allowed. FDA Access Data+1

14. Gabapentin (Neurontin®). Class: neuromodulator. Purpose: Neuropathic components of back pain. Mechanism: α2δ-subunit modulation. Side effects: sedation, dizziness. FDA Access Data+1

15. Pregabalin (Lyrica®). Class: neuromodulator. Purpose: Neuropathic pain when appropriate. Dose: typically 150–300 mg/day initially, titrated. Side effects: dizziness, weight gain, edema. FDA Access Data+1

16. Baclofen (Ozobax®/Lyvispah®). Class: antispasticity agent (GABA-B agonist). Purpose: Muscle spasm relief in painful scoliosis patterns when indicated. Side effects: sedation; taper to avoid withdrawal. FDA Access Data+1

17. Cyclobenzaprine (Flexeril®/Amrix®). Class: skeletal muscle relaxant. Purpose: Short-course relief of acute spasm. Side effects: drowsiness; avoid with other sedatives. FDA Access Data+1

18. Ondansetron (Zofran®). Class: 5-HT3 antagonist antiemetic. Purpose: Prevent/treat post-operative nausea for eye/spine procedures. Risks: QT prolongation, interactions. FDA Access Data+1

19. Topical ocular lubricants (various). Class: demulcents. Purpose: Comfort after eye surgery or with surface irritation. Mechanism: Tear film support. (OTC monograph products; check surgeon’s instructions.)

20. Prophylactic peri-operative antibiotics/anti-inflammatories per surgeon protocol (agent as above). Purpose: Reduce infection/inflammation risks. Mechanism: Target common pathogens; suppress prostaglandins. FDA Access Data+1

Dietary molecular supplements

Supplements do not cure BSAS. Use them to support general eye/spine health only if your clinicians agree and if diet is insufficient.

1. Vitamin D. Dose: per age/status (often 600–800 IU/day for adults unless deficient). Function: bone health; muscle/nerve function. Mechanism: boosts calcium absorption and bone mineralization. Note: avoid excess. Office of Dietary Supplements+1

2. Calcium. Dose: age-appropriate (≈1000–1200 mg/day total from diet+supplement). Function: skeletal strength. Mechanism: mineral for bone matrix; works with vitamin D. Office of Dietary Supplements

3. Lutein + Zeaxanthin (AREDS2 blend component). Function: macular pigment support; antioxidant role. Mechanism: filters blue light; quenches oxidative stress. Evidence: AREDS2 favored lutein/zeaxanthin over beta-carotene for AMD risk—extrapolate cautiously to low-vision care. National Eye Institute+1

4. Omega-3 fatty acids (fish/algal DHA/EPA). Function: general cardiometabolic and ocular surface support. Mechanism: anti-inflammatory lipid mediators. Evidence: mixed for dry eye; not proven for retinal disease. American Academy of Ophthalmology+1

5. Vitamin A (avoid excess). Function: essential for phototransduction and ocular surface. Mechanism: component of rhodopsin; supports epithelial health. Caution: toxicity if overdosed; smokers should avoid beta-carotene forms. Office of Dietary Supplements+1

6. Magnesium (if low dietary intake). Function: muscle/nerve support. Mechanism: cofactor in neuromuscular transmission; may aid muscle relaxation. (ODS general guidance.)

7. B-complex (B12/folate as needed). Function: nerve health and energy metabolism. Mechanism: coenzymes in myelin/DNA synthesis. (General nutrition guidance.)

8. Protein sufficiency (whey/plant protein if needed). Function: supports back/core strengthening, surgical recovery. Mechanism: provides amino acids for muscle repair. (Sports/rehab nutrition consensus.)

9. Antioxidant-rich diet pattern (not pill). Function: overall vascular/ocular health. Mechanism: colorful vegetables/berries supply carotenoids and polyphenols; food-first approach preferred. (NEI/AREDS context.) National Eye Institute

10. Hydration and fiber (dietary). Function: comfort, regularity with analgesics; overall wellness. Mechanism: prevents constipation exacerbated by pain meds. (Clinical practice.)

---

Immunity booster / regenerative / stem-cell drugs

Currently, there are no FDA-approved “immunity-boosting,” regenerative, or stem-cell drugs for BSAS or its core features. Unregulated “stem-cell” injections for the eye have caused severe harm and blindness; they should be avoided outside legitimate clinical trials. Evidence-based immune support consists of vaccinations (per national schedules), nutrition, sleep, and exercise—not special drugs. For retinal detachment, lens subluxation, or scoliosis, surgery and rehabilitation—not stem cells—are the proven options today. (AAO/NEI safety perspective; retina/surgery guidelines.) EyeWiki+1

---

Surgeries

1. Retinal detachment repair (pneumatic retinopexy / scleral buckle / pars plana vitrectomy).
   Why: To reattach the retina and prevent permanent vision loss. Choice depends on break location/size and surgeon judgment. EyeWiki+1

2. Prophylactic laser/cryotherapy for retinal tears (when indicated).
   Why: Seal symptomatic tears to prevent progression to detachment. American Academy of Ophthalmology

3. Lens surgery for subluxation/dislocation (lensectomy ± capsular tension ring; IOL fixation).
   Why: Restore optical focus, relieve inflammation/pressure, and prevent corneal damage; approach tailored to zonular status. AAO Journal+1

4. Posterior chamber IOL fixation or alternative IOL strategies.
   Why: Provide stable vision when the natural lens/zonules are not usable. American Academy of Ophthalmology

5. Spine surgery for progressive/debilitating scoliosis (fusion, selective tethering in select adolescents).
   Why: Halt progression, correct deformity, relieve pain/organ compromise when conservative care fails. OrthoInfo+1

---

Preventions

1. Keep regular dilated eye exams with a retina-trained ophthalmologist. EyeWiki

2. Learn and act fast on warning signs (flashes, floaters, curtain). EyeWiki

3. Use protective eyewear for sports/risks. EyeWiki

4. Start scoliosis-specific PT early; follow bracing plans if prescribed. BioMed Central

5. Maintain bone health (vitamin D, calcium, weight-bearing exercise). Office of Dietary Supplements

6. Don’t smoke; limit alcohol. (Public-health consensus.)

7. Optimize lighting/contrast at home to avoid falls. National Eye Institute

8. Keep post-op follow-ups strictly if you have eye surgery. American Academy of Ophthalmology

9. Manage pain and sleep to stay active in rehab. (Rehab practice.)

10. Avoid unproven stem-cell/online “cures.” (AAO safety stance.) EyeWiki

---

When to see doctors (urgent vs routine)

Urgent, same-day care: sudden flashes/floaters, a dark curtain in vision, severe eye pain/headache with halos, sudden vision drop, eye trauma. These can signal retinal detachment or acute pressure rise. EyeWiki
Prompt appointment: new double vision, lens “shimmering,” increasing glare, increasing back pain or fast curve changes, breathing trouble from kyphoscoliosis, brace problems. OrthoInfo
Routine: scheduled low-vision, retina, and spine reviews for surveillance and rehab progression. National Eye Institute

---

Foods to eat and to limit

Eat more:

1. Leafy greens (lutein/zeaxanthin: spinach, kale). National Eye Institute
2. Fatty fish (DHA/EPA) 1–2×/week if not contraindicated. American Academy of Ophthalmology
3. Citrus/berries (vitamin C/antioxidants).
4. Orange/yellow veg (carotenoids). Office of Dietary Supplements
5. Dairy/fortified plant milks (calcium + vitamin D). Office of Dietary Supplements
6. Eggs, nuts, legumes (protein for muscle repair).
7. Whole grains (energy and fiber).
8. Adequate water (comfort, healing).
9. Olive oil/avocado (healthy fats aid vitamin absorption).
10. High-fiber meals (counter constipation from pain meds).

Limit/Avoid:

1. Smoking (any form)—eye and bone risks.
2. Excess alcohol—bone/muscle and fall risk.
3. Ultra-processed snacks—low nutrient density.
4. Very high sodium—fluid balance/blood pressure.
5. Excess added sugars—inflammation/weight gain.
6. Mega-doses of vitamin A/beta-carotene—toxicity risk. Office of Dietary Supplements
7. Unverified supplements—quality concerns.
8. High-impact eye-risk sports without protection.
9. Crash diets—muscle/bone loss.
10. Grapefruit only if drugs you take have interactions (ask pharmacy).

---

FAQs

1. Is BSAS curable?
   Not today. Care targets vision, spine, and hand/foot features to protect function and independence. Genetic Rare Disease Center

2. What eye problems are most concerning?
   Lens instability and retinal detachment—prompt diagnosis and treatment are vision-saving. EyeWiki

3. Can glasses fix BSAS?
   Glasses help refractive error but cannot correct lens subluxation or retinal disease; surgery/rehab may be needed. AAO Journal

4. Does everyone with BSAS go blind?
   No. Severity varies. Early surveillance and timely treatment improve outcomes. Munis Dundar

5. Are there gene tests?
   A specific BSAS gene is not established; genetic testing is used to exclude related syndromes. Orpha.net

6. What is low-vision rehabilitation?
   A program that teaches tools/skills to maximize remaining vision and independence. National Eye Institute

7. When is retina surgery needed?
   When tears/detachments are found or when vision is threatened. EyeWiki

8. Can exercises straighten scoliosis?
   Exercises can improve function and may slow progression in mild curves; braces are used when criteria are met. BioMed Central

9. Are back braces safe?
   Yes when prescribed/fitted by specialists and worn as directed. OrthoInfo

10. Do omega-3 pills protect vision?
    Evidence is mixed for dry eye and not proven for retinal disease; food sources are fine. American Academy of Ophthalmology+1

11. Are “stem-cell cures” available?
    No. Avoid clinics advertising unproven injections; harm has occurred. EyeWiki

12. How often should I see the eye doctor?
    As your specialist advises; typically more often during growth or if symptoms change. EyeWiki

13. What pain medicines are safest?
    Use the lowest effective dose and follow labels; many NSAIDs have GI/CV warnings—ask your doctor, especially around surgery. FDA Access Data+1

14. Can nutrition help my spine?
    Adequate vitamin D and calcium support bone health; nutrition complements but does not replace bracing/therapy. Office of Dietary Supplements

15. What specialists should be on my team?
    Retina/ophthalmology, low-vision rehab, orthopedic spine, physical therapy, and genetics as needed. National Eye Institute+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 28, 2025.